Researchers Urge More Company-To-Company Collaboration On Clinical Trials
This article was originally published in The Gray Sheet
With cost and time commitments ballooning for device and drug clinical development, some prominent researchers are pressing for companies with similar products to join together on new FDA pivotal trials rather than go it alone.
You may also be interested in...
Data reported last week could hasten moves by electrophysiologists to implant price-premium cardiac resynchronization therapy systems rather than conventional defibrillators in patients with earlier stage heart failure.
FDA is contributing $1.5 million to a large, collaborative clinical study designed to find out the optimum length of time to give anti-clotting drugs to patients with coronary drug-eluting stents
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.